M. Lazarov

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE In a recent phase II study of onartuzumab (MetMAb), patients whose non-small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a(More)
7529 Background: MetMAb, a monovalent anti-cMet receptor antibody, inhibits HGF-mediated activation of c-Met. The Phase II study testing MetMAb in combination with erlotinib in patients with advanced(More)